Business Wire

New York Jets Announce IdentoGO by IDEMIA as Official Identity Security and Biometrics Partner

Del

The New York Jets have announced today a new multi-year partnership with IdentoGO by IDEMIA, the country’s preeminent identity-related service provider and exclusive provider of TSA Pre✓®. The agreement marks IdentoGO’s first NFL partnership and first exclusive sponsorship in professional sports. The deal makes IdentoGO the Official Identity Security and Biometrics Partner of the New York Jets.

“We are proud to be the first sports team to partner with an industry leader like IdentoGO,” said New York Jets President Neil Glat. “IdentoGO’s commitment to innovation and providing the best possible customer experience tightly aligns with our own philosophy. We look forward to working with them to explore new ways to provide our fans with access to new and improved technology to improve the gameday experience.”

The new deal will also provide Jets fans with the opportunity to register for expedited security screening for travelers (TSA Pre✓®) at MetLife Stadium on game days. The activation, which will take place at all Jets home games during the 2017 season, will be located between lots E and F, outside the MetLife gate. For more information on TSA Pre✓® enrollment, please visit identogo.com/jets.

“It is our mission and responsibility to make our security solutions, like the TSA Pre✓® program, available to as many people as possible,” said Didier Lamouche, CEO of IDEMIA, the company that provides IdentoGO services. “Our partnership with the Jets allows us to reach as many as 75,000 fans at each home game and enroll a high percentage of those people into the proven safe and secure program. We are thrilled to be working with such a world-class organization.”

As the Official Identity Security and Biometrics Partner of the Jets, IdentoGO will be the presenting partner of the New York Jets Fan Hall of Fame – an initiative launched earlier this season to celebrate the ultimate Jets fan. Culminating in an induction ceremony during the final home game of the 2017 season, the inaugural New York Jets Fan Hall of Fame inductees will receive recognition at the Atlantic Health Jets Training Center, recognition in the Jets Experience at all home games and events, a commemorative varsity jacket and Coaches Club tickets when the Jets take on the Chargers on December 24, 2017.

Additionally, the partnership includes an innovative pilot program focused on leveraging IdentoGO’s wide-range of technology with the sole purpose to be potentially implemented as part of the fan experience at New York Jets home games and other Jets events throughout the year. The partnership also includes signage at MetLife Stadium, as well as digital, and social assets.

# # #

About IdentoGO by IDEMIA
IdentoGO by IDEMIA provides a wide range of identity-related services with the primary service being the secure capture and transmission of electronic fingerprints for employment, certification, licensing and other verification purposes – in professional and convenient locations. IdentoGO is the exclusive provider of TSA Pre✓®, a program that allows pre-vetted travelers to move through security more quickly and easily when departing airports in the U.S.

About IDEMIA
OT-Morpho is now IDEMIA, the global leader in trusted identities for an increasingly digital world, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment.

Contact information

Press
IDEMIA
Elizabeth MARSHALL, T 978-215-2513
elizabeth.marshall@us.idemia.com
or
New York Jets
Meghan GILMORE, T 973-549-4684

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovation15.8.2018 17:05Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with a Stevie® Award in the Innovation in Customer Service Management, Planning & Practice category for its ultra-responsive, premium level service in the Asia-Pacific region. This honor marks the Company’s 12th Stevie Award win this year, and the second consecutive year the Company has been recognized by the Asia-Pacific Stevie Awards. Rimini Street recently earned Stevie Awards in several categories, including Company of the Year from the 2018 American Business Awards® and Customer Service Department of the Year from the 2018 Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005580/en/ Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovat